KVUE has slipped further since its August 13 Q3 print, with the stock now at $18.80 — down 1.3% on the week and 1% over the past month — as the Street quietly walked back price targets even as earnings results posed no outright alarm.
The most telling shift in positioning this week came from the borrow market, and it points in an unexpected direction. Cost to borrow collapsed to just 0.07% — down more than 80% versus last week and more than 70% against a month ago. That is essentially free to borrow, and it arrives alongside availability that is, for practical purposes, unlimited: nearly 1.9 billion shares are available to lend against short interest of roughly 62.5 million shares. There is no friction in the lending market whatsoever. Short interest itself has crept higher — up about 2.4% on the week and nearly 6% over the past month to 3.3% of the float — but that remains a low absolute level, and with borrow this cheap and shares this plentiful, there is no mechanical pressure in either direction. The ORTEX short score has drifted down slightly, from 35.1 on August 7 to 34.3 now, which is consistent with a positioning picture that is neither crowded nor under stress. Options reinforce that read: the put/call ratio at 0.40 is fractionally above its 20-day average of 0.39 and barely 0.8 standard deviations away from it, placing options sentiment squarely in neutral territory.
What makes this week mildly interesting is the divergence between the stock's downward drift and the analyst community's stubborn refusal to change direction. UBS lowered its price target to $19.00 from $20.00 on August 11 — the only notable move in the past ten days — while maintaining a Neutral rating. That trim is consistent with the pattern since the Q2 print: targets have been nudging down in small steps, never a dramatic cut, but never a conviction upgrade either. The consensus mean target of $19.50 now sits less than 4% above the current price. The bull case centers on brand durability across self-care franchises — Tylenol, Neutrogena, Listerine — and a dividend yield running near 4.5%, which factor scores rank at the 82nd percentile. The bear case is structural: earnings momentum is weak (30th percentile on 90-day EPS momentum), forward EPS growth expectations are roughly flat year-on-year, and the stock trades at about 15.8x earnings — not stretched, but not obviously cheap for a business with limited visible growth catalysts.
Institutional ownership presents the one genuinely active subplot. FMR (Fidelity) added over 14 million shares in the most recent reporting period — the largest addition among the top holders. BlackRock added another 5.5 million. Both moves suggest large passive and active index-oriented buyers continue absorbing the float, which likely explains why short sellers face no borrow constraint: the institutional lend pool is deep and growing. Starboard Value, the activist holder with a 1.4% stake, reported no change as of late June — a position worth monitoring as the post-J&J separation operational narrative develops.
Earnings reactions have been modest in both directions. The Q2 print in early August produced a 2.2% single-day drop and a 2.4% five-day loss. The August 13 release registered a 1.2% bounce the following day. Neither move points to a high-volatility event stock; the market is treating each quarterly print as an incremental update rather than a thesis-changer. The next event is scheduled for November 6.
The key thing to watch heading into that November print is whether the gap between FMR's recent buying conviction and UBS's quiet target-trimming narrows — and whether the post-separation organic growth story generates enough momentum to lift analyst sentiment out of its extended neutral holding pattern.
See the live data behind this article on ORTEX.
Open KVUE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
